Reconnect Labs is a Swiss, clinical stage pharmaceutical company developing Regenerative Therapeutics™ for mental health at the forefront of neuroscience and precision psychopharmacology. Led by neuroscientists from the University of Zurich Psychiatric University Clinic (PUKZH), Reconnect translates 30 years of in-human research and clinical practice to solve for the safety, efficacy and commercialization challenges of generation 1 psychoplastogens, Reconnect originated a portfolio of psychoactive formulations for affective and neurodegenerative disorders, chronic pain and insomnia.
Location: Switzerland, Zurich, Winterthur
Employees: 1-10
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | Esperante | esperante.... |
Mentions in press and media 3
| Date | Title | Description |
| 05.11.2024 | Bio Europe in Stockholm hosts 33 Swiss companies | Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| 27.03.2023 | Here are the 15 hottest startups in the psychedelics industry, according to top investors | From left: Sherry Rais, a cofounder and the CEO of Enthea; Mark Rus, the CEO of Delix Therapeutics; Jackie von Salm, a cofounder and the CSO of Psilera; Jimmy Qian, a cofounder and the president of Osmind. Sherry Rais/Enthea; Mark Rus/Delix... |
| 16.03.2023 | Swiss startups prepare to visit the US East Coast |